Ascletis Pharma Inc
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory … Read more
Ascletis Pharma Inc (ASCLF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.093x
Based on the latest financial reports, Ascletis Pharma Inc (ASCLF) has a cash flow conversion efficiency ratio of -0.093x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-172.99 Million) by net assets ($1.87 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ascletis Pharma Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Ascletis Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Ascletis Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ascletis Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dhanuka Agritech Limited
NSE:DHANUKA
|
0.026x |
|
KERRY LOG.NETWORK HD-50
F:KYL
|
N/A |
|
Jiangsu Huachen Transformer
SHG:603097
|
0.000x |
|
Great Tree Pharmacy Co Ltd
TWO:6469
|
0.120x |
|
Giordano International Limited
PINK:GRDZF
|
0.212x |
|
NanJing Sanchao Advanced Materials Co Ltd
SHE:300554
|
-0.061x |
|
Grupo Clarin S.A.
BA:GCLA
|
0.050x |
|
J.Kumar Infraprojects Limited
NSE:JKIL
|
0.129x |
Annual Cash Flow Conversion Efficiency for Ascletis Pharma Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Ascletis Pharma Inc from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.97 Billion | $-341.58 Million | -0.174x | -182.24% |
| 2023-12-31 | $2.34 Billion | $-144.16 Million | -0.062x | -9.75% |
| 2022-12-31 | $2.54 Billion | $-142.45 Million | -0.056x | -4.17% |
| 2021-12-31 | $2.73 Billion | $-146.93 Million | -0.054x | -89.06% |
| 2020-12-31 | $2.98 Billion | $-84.91 Million | -0.028x | -27.34% |
| 2019-12-31 | $3.32 Billion | $-74.34 Million | -0.022x | +20.65% |
| 2018-12-31 | $3.43 Billion | $-96.59 Million | -0.028x | +87.62% |
| 2017-12-31 | $869.83 Million | $-198.06 Million | -0.228x | -645.29% |
| 2016-12-31 | $409.08 Million | $-12.50 Million | -0.031x | -- |